An AllTrials project

NCT03742037: A reported trial by Idorsia Pharmaceuticals Ltd.

This trial has reported on time, in line with the regulations.

Full data

Full entry on ClinicalTrials.gov NCT03742037
Title A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Subjects With Moderate to Severe Systemic Lupus Erythematosus (SLE)
Results Status Reported
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date Dec. 21, 2018
Completion date Aug. 31, 2021
Required reporting date Aug. 31, 2024, midnight
Actual reporting date Aug. 7, 2023
Date last checked at ClinicalTrials.gov Feb. 9, 2024
Days late None